Caris Life Sciences (CAI) Amortizatization of Intangibles (2024 - 2026)
Caris Life Sciences (CAI) posted quarterly Amortizatization of Intangibles of $2.6 million for Q1 2026, up 34.91% year-over-year from $1.9 million in Q1 2025, and up 333.72% quarter-over-quarter from $605000.0 in Q4 2025.
Analysis
Caris Life Sciences (CAI) Amortizatization of Intangibles (2024 - 2026) Analysis & Trends
Caris Life Sciences' Amortizatization of Intangibles history runs 3 years deep, the most recent figure standing at $2.6 million for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 34.91% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $13.4 million (up 81.5% YoY), while the FY2025 annual figure was $12.8 million, up 81.0% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $2.6 million, up from $605000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $7.8 million in Q2 2025, with the low at $605000.0 in Q4 2025.
- The 3-year median for Amortizatization of Intangibles is $1.9 million (2024), against an average of $2.6 million.
- Peak annual rise in Amortizatization of Intangibles reached 348.01% in 2025, while the deepest fall reached 68.26% in 2025.
- Caris Life Sciences' Amortizatization of Intangibles stood at $1.9 million in 2024, then tumbled by 68.26% to $605000.0 in 2025, then jumped by 333.72% to $2.6 million in 2026.
- Business Quant data shows CAI's Amortizatization of Intangibles at $2.6 million in Q1 2026, $605000.0 in Q4 2025, and $2.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Caris Life Sciences | 7.08 Bn | 6.28 Bn | 182.38 Mn | 298,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 298,000.00 |
| Mar 31, 2026 | 2.62 Mn |
| Dec 31, 2025 | 605,000.00 |
| Sep 30, 2025 | 2.46 Mn |
| Jun 30, 2025 | 7.76 Mn |
| Mar 31, 2025 | 1.95 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Sep 30, 2024 | 1.83 Mn |
| Jun 30, 2024 | 1.73 Mn |